Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NETWORK 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Leukemia, Myeloid, Acute 1Leukemia, Biphenotypic, Acute 1Leukemia 1Congenital Abnormalities 1

Interventions

Cytarabine 30Daunorubicin 15Gene Expression Profiling 9Gemtuzumab 9Flow Cytometry 9Idarubicin 8Mitoxantrone 7sargramostim 6fludarabine 6Polymerase Chain Reaction 6Methotrexate 6Filgrastim 6Etoposide 6Cyclophosphamide 6Busulfan 6fludarabine phosphate 5Specimen Handling 5merphos 4Whole-Body Irradiation 4Stem Cell Transplantation 4Peripheral Blood Stem Cell Transplantation 4Mycophenolic Acid 4Biopsy 4Tacrolimus 3Observation 3Melphalan 3Immunologic Techniques 3Hydrocortisone 3DNA Methylation 3Clofarabine 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Leukemia, Myeloid, Acute × lestaurtinib × Clear all
NCT00469859 2017-03-15

Lestaurtinib, Cytarabine, and Idarubicin in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia

Children's Oncology Group

Phase 1/2 Completed
14 enrolled 9 charts
Other hematologic neoplasm

Congenital Abnormalities, Leukemia, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡